RenovoRx, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1M | $43,000 | — | — | — |
| Cost of revenue | $327,000 | $0 | — | — | — |
| Gross profit | $796,000 | $43,000 | — | — | — |
| Selling, general & administrative | $7.0M | $5.0M | $5.7M | — | — |
| Research and development | $6.3M | $6.0M | $5.7M | $4.3M | $3.0M |
| Operating expenses | $13.3M | $11.0M | $11.4M | $9.9M | $5.7M |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Pretax income | -$11.2M | -$8.8M | — | — | — |
| Income tax expense | $2,000 | $1.7M | — | — | — |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M |
| Balance Sheet | |||||
| Cash and equivalents | $7.0M | $7.2M | $1.2M | $4.4M | $15.2M |
| Current assets | $7.9M | $7.8M | $1.5M | $7.3M | $16.3M |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M |
| Current liabilities | $2.0M | $1.9M | $1.2M | $1.1M | $938,000 |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938,000 |
| Stockholders' equity | $5.4M | $4.5M | $3.0M | $6.2M | $15.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Depreciation and amortization | $2,000 | $0 | — | — | — |
| Stock-based compensation | $1.3M | $1.2M | $1.1M | $644,000 | $147,000 |
| Capital expenditure | $2,000 | $12,000 | — | — | — |
| Free cash flow | -$11.0M | -$9.1M | — | — | — |
Shares outstanding 45.1M · Free float 86.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.